Seattle Genetics announces first patient dosed in phase 2 innovaTV 207 trial
Seattle Genetics announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating activity, safety and tolerability of tisotumab vedotin as monotherapy in selected solid tumors with high Tissue Factor expression. Tisotumab vedotin is being developed in with Genmab. July 12, 2018
